LifeMD, Inc. (NASDAQ:LFMD) Insider Sells $183,750.00 in Stock

LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) insider Eric Harold Yecies sold 15,000 shares of the stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $12.25, for a total transaction of $183,750.00. Following the sale, the insider now owns 16,100 shares of the company's stock, valued at $197,225. This trade represents a 48.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

LifeMD Trading Up 10.9%

Shares of NASDAQ:LFMD traded up $1.48 on Wednesday, reaching $15.06. 3,098,569 shares of the company were exchanged, compared to its average volume of 1,046,482. The company has a 50-day moving average of $9.38 and a 200-day moving average of $6.89. The firm has a market cap of $684.48 million, a price-to-earnings ratio of -44.29 and a beta of 2.42. LifeMD, Inc. has a 1-year low of $3.99 and a 1-year high of $15.29.

LifeMD (NASDAQ:LFMD - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $0.01 EPS for the quarter, topping analysts' consensus estimates of ($0.04) by $0.05. The company had revenue of $65.70 million for the quarter, compared to analysts' expectations of $62.47 million. As a group, analysts forecast that LifeMD, Inc. will post -0.56 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on LFMD. B. Riley upgraded LifeMD to a "strong-buy" rating in a research note on Tuesday, March 11th. HC Wainwright restated a "buy" rating and set a $14.00 price objective on shares of LifeMD in a research report on Wednesday, April 30th. Cantor Fitzgerald restated an "overweight" rating and issued a $15.00 target price on shares of LifeMD in a research note on Tuesday, March 11th. Finally, BTIG Research boosted their price target on shares of LifeMD from $15.00 to $18.00 and gave the stock a "buy" rating in a research note on Wednesday. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, LifeMD has an average rating of "Buy" and an average target price of $12.00.

Hedge Funds Weigh In On LifeMD

Hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC purchased a new stake in shares of LifeMD in the first quarter valued at about $35,000. CWM LLC raised its position in shares of LifeMD by 17.5% during the 1st quarter. CWM LLC now owns 9,050 shares of the company's stock worth $49,000 after purchasing an additional 1,351 shares during the last quarter. ProShare Advisors LLC purchased a new stake in LifeMD in the 4th quarter valued at approximately $51,000. Oxford Asset Management LLP purchased a new stake in LifeMD in the 4th quarter valued at approximately $52,000. Finally, Balyasny Asset Management L.P. acquired a new stake in LifeMD during the 4th quarter valued at $52,000. 35.52% of the stock is owned by hedge funds and other institutional investors.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.